Sadaf Farsinejad

Feb 15, 2025 | biorxiv.org | Sadaf Farsinejad |Daniel Centeno |Jan-Savas Carstens |Teagan Polotaye

AbstractThe role of extracellular matrix adhesion components in the modulation of the treatment sensitivity of ovarian cancer (OC) cells is not well understood. Analysis of ovarian cancer TCGA gene expression data sets revealed an inverse correlation between genes involved in cell-cycle progression and extracellular matrix interactions including laminin-binding receptor integrin 4, a major component of extracellular matrix adhesion.

Jun 9, 2024 | mdpi.com | Daniel Centeno |Sadaf Farsinejad |Elena Kochetkova |Tatiana Volpari

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

May 14, 2024 | biorxiv.org | Daniel Centeno |Sadaf Farsinejad |Elena Kochetkova |Tatiana Volpari

AbstractTaurine, a non-proteogenic amino acid, and commonly used nutritional supplement can protect various tissues from degeneration associated with the action of the DNA-damaging chemotherapeutic agent cisplatin. Whether and how taurine protects human ovarian cancer (OC) cells from DNA damage caused by cisplatin is not well understood. We have found that OC ascites-derived cells contained significantly more intracellular taurine than cell cultures modeling OC.

Aug 26, 2023 | biorxiv.org | Daniel Centeno |Sadaf Farsinejad |Elena Kochetkova |Tatiana Volpari

AbstractLoss of treatment-induced ovarian carcinoma (OC) growth suppression poses a major clinical challenge because it leads to disease recurrence. Therefore, there is a compelling need for well- -tolerated approaches that can support tumor growth-suppression after therapy is stopped. We have profiled ascites as OC tumor microenvironments to search for potential non-toxic soluble components that would activate tumor suppressor pathways in OC cells.

Jul 31, 2023 | biorxiv.org | Daniel Centeno |Sadaf Farsinejad |Elena Kochetkova |Tatiana Volpari

Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.